R&D Pipeline
Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.
Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.
Neurodegenerative Diseases
c-Abl
Parkinson, ALS
c-Abl/LRRK2
Parkinson, ALS
c-Abl/PET
PET tracer for c-Abl therapeutic
Undisclosed
Neurological rare disease
Oncology
HPK1
Oncology
GCN2
Oncology
Rare Diseases
Undisclosed
Rett syndrome and other genetic diseases
Platform Technology
1ST-501
AI Drug Discovery Engine